DUBLIN , June 16, 2022 /PRNewswire/ -- The "Anti-aging Therapeutics Market - Distribution by Type of Molecule, Type of Aging and Key Geographies - Industry Trends and Global Forecasts, 2022-2040" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape and future potential of anti-aging therapeutics over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain.  The advancements in health care and available technologies have inadvertently led to an increase in the life expectancy of individuals. However, this has also led to a rise in the aging population worldwide. According to the United Nations, the aforementioned trend is one of the key transformations observed in the 21st century; it is expected to have an impact on all sections of the society.

Aging is linked to a variety of diseases, including cardiovascular disorders, neurodegenerative disorders, oncological disorders and musculoskeletal disorders, which further puts heavy economic and psychological burden on the patients, their families and the society.

As per the World Health Organization, in 2020, close to 1 billion people were estimated to be aged 65 or above, globally. In addition, the share of elderly population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging biology is still a largely unexplored field, in terms of the development of safe and effective novel pharmacotherapies. Anti-aging therapeutics, therefore, is an emerging field of medical science focused on reducing or reversing the underlying causes of aging through different mechanisms, in order to extend healthy lifespan of humans. Given the rapidly growing aging population, the ongoing efforts to discover drugs that enhance the lifespan of an individual by targeting the pathogenesis of aging have become a popular topic for research. At present, various anti-aging products and devices, including direct-to-consumer nutraceuticals, plastic surgeries, cosmetics, skincare products and devices, are available in the market to slow the process of aging.

Further, several start-ups and academic / research institutes across the world are evaluating various types of anti-aging therapeutics, including stem cell therapies, metformin, rapamycin, resveratrol and senolytics (drugs that selectively clear senescent cells), in multiple preclinical / clinical studies.

Owing to the encouraging results demonstrating the ability of novel drugs in delaying the aging process, capital investments worth USD 4 billion have been made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid to long-term. Amongst other elements, the report includes:

A detailed assessment of the current market landscape of anti-aging therapeutics, featuring information on phase of development (commercial, phase II, phase I / II, phase I, clinical (phase unknown), discovery / preclinical and undisclosed), type of aging (cellular aging, metabolic aging, immune aging, others and undisclosed), type of molecule (biologics and small molecules), mechanism of action (senolytic, cell regeneration, mammalian target of rapamycin (mTOR) inhibitor / modulator, adenosine monophosphate (AMP)-kinase / AMP activator, mitochondria inhibitor / modulator and others) and type of developer (industry and non-industry). In addition, the chapter features analyses of anti-aging therapeutic developers based on parameters, such as year of establishment, company size, location of headquarters and leading developers (in terms of number of pipeline candidates).

A competitiveness analysis of anti-aging therapeutic developers, based on various relevant parameters, namely supplier power (based on the experience of the developer) and company competitiveness (based on highest phase of development, type of aging and type of molecule).

An analysis of partnerships that have been inked by stakeholders engaged in this domain, during the period 2018-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, most active players (in terms of number of partnerships), type of partner and regional distribution of collaborations.

A detailed analysis of investments that have been made into companies which are developing proprietary anti-aging therapeutics, during period 2018-2022. The various types of funding instances reported in this domain include pre-seed financing, seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants, crowdfunding, and donations.

An in-depth analysis of the various patents that have been filed / granted related to anti-aging therapeutics, during 2018-2022, taking into consideration parameters, such as publication year, type of patent, geographical region, CPC symbols, key focus areas, type of applicant, patent age and leading players (in terms of size of intellectual property portfolio). It also features a patent benchmarking analysis and a detailed valuation analysis.

A detailed review of more than 220 peer-reviewed, scientific articles related to research on anti-aging therapeutics, during the period 2018-2022, based on several relevant parameters, such as year of publication, type of publication, popular keywords and geography of affiliations. The chapter also provides information on the most popular publisher, most popular journal, most popular affiliations and most popular funding institutes (in terms of number of articles published).

A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.

Elaborate profiles of prominent players engaged in the development of anti-aging therapeutics, featuring a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook.

Who are the leading players engaged in the development of anti-aging therapeutics?

What types of partnership models are commonly adopted by industry stakeholders engaged in this industry?

Who are the key investors in the anti-aging therapeutics domain?

How is the intellectual property landscape in this field likely to evolve in the foreseen future?

What is the evolving trend of publications focused on anti-aging therapeutics?

What are the key value drivers that are likely to influence the evolution of this upcoming market?

How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. MARKET LANDSCAPE 5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Assumptions and Key Parameters 5.3. Methodology 5.4. Anti-aging Therapeutics: Company Competitiveness Analysis 5.4.1. Small Companies 5.4.2. Mid-sized and Large Companies 6. PARTNERSHIPS AND COLLABORATIONS 6.1. Chapter Overview 6.2. Anti-aging Therapeutics: Partnerships and Collaborations 6.2.1 Analysis by Year of Partnership 6.2.2. Analysis by Type of Partnership 6.2.3. Analysis by Year and Type of Partnership 6.2.4. Leading Players: Analysis by Number of Partnerships 6.2.5. Analysis by Type of Partner 6.2.6. Analysis by Type of Agreement 6.2.7. Analysis by Region 6.2.7.1. Intercontinental and Intracontinental Deals 6.2.7.2. International and Local Deals 7. FUNDING AND INVESTMENTS 7.1. Chapter Overview 7.2. Anti-aging Therapeutics: Funding and Investments 7.2.1. Analysis of Instances by Year 7.2.2. Analysis of Amount Invested by Year 7.2.3 Analysis of Instances by Type of Funding 7.2.4. Analysis of Amount Invested by Type of Funding 7.2.5. Analysis by Type of Investor 7.2.6. Analysis by Focus Area 7.2.7. Analysis of Amount Invested by Region 7.2.8. Analysis of Amount Invested by Country 7.2.9. Most Active Investors: Analysis by Number of Instances 7.2.10 . Most Active Players: Analysis by Number of Instances 7.2.11 . Most Active Players: Analysis by Amount Invested 8. PATENT ANALYSIS 8.1. Chapter Overview 8.2. Scope and Methodology 8.3. Anti-aging Therapeutics: Patent Analysis 8.3.1. Analysis by Type of Patent 8.3.2. Analysis by Patent Publication Year 8.3.3. Analysis of Granted Patents by Year 8.3.4. Analysis by Geography 8.3.5. Analysis by CPC Symbols 8.3.6. Analysis by Type of Applicant 8.3.7. Analysis by Emerging Focus Areas 8.3.8. Analysis by Patent Age 8.3.9. Leading Industry Players: Analysis by Number of Patents 8.3.10 . Leading Non-Industry Players: Analysis by Number of Patents 8.3.11 . Leading Individual Assignees: Analysis by Number of Patents 8.4. Anti-aging Therapeutics: Patent Benchmarking 8.4.1. Analysis by Patent Characteristics 8.5. Anti-aging Therapeutics: Patent Valuation 9. PUBLICATION ANALYSIS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. Anti-aging Therapeutics: Publication Analysis 10. PORTER'S FIVE FORCES ANALYSIS 11. COMPANY PROFILES 11.1. AgelessRx 11.1.1. Company Overview 11.1.2. Product Portfolio 11.1.3. Recent Developments and Future Outlook 11.2. ANOVA Institute for Regenerative Medicine 11.2.1. Company Overview 11.2.2. Product Portfolio 11.2.3. Recent Developments and Future Outlook 11.3. Betterhumans 11.3.1. Company Overview 11.3.2. Product Portfolio 11.3.3. Recent Developments and Future Outlook 11.4. BioAge Labs 11.4.1. Company Overview 11.4.2. Product Portfolio 11.4.3. Recent Developments and Future Outlook 11.5. bioXcellerator 11.5.1. Company Overview 11.5.2. Product Portfolio 11.5.3. Recent Developments and Future Outlook 11.6. Cambrian Biopharma 11.6.1. Company Overview 11.6.2. Product Portfolio 11.6.3. Recent Developments and Future Outlook 11.7. Gero.ai 11.7.1. Company Overview 11.7.2. Product Portfolio 11.7.3. Recent Developments and Future Outlook 11.8. Mayo Clinic 11.8.1. Company Overview 11.8.2. Product Portfolio 11.8.3. Recent Developments and Future Outlook 11.9. Rejuvenate Bio 11.9.1. Company Overview 11.9.2. Product Portfolio 11.9.3. Recent Developments and Future Outlook 11.10. UT Health San Antonio 11.10.1. Company Overview 11.10.2. Product Portfolio 11.10.3. Recent Developments and Future Outlook 12. MARKET FORECAST AND OPPORTUNITY ANALYSIS 12.1. Forecast Methodology and Key Assumptions 12.2. Global Anti-aging Therapeutics Market, 2022-2040 12.2.1. Anti-aging Therapeutics Market: Analysis by Type of Molecule 12.2.2. Anti-aging Therapeutics Market: Analysis by Type of Aging 12.2.3. Anti-aging Therapeutics Market: Analysis by Geography 12.2.3.1. Anti-aging Therapeutics Market in North America , 2022-2040 12.2.3.2. Anti-aging Therapeutics Market in Europe , 2022-2040 12.2.3.3. Anti-aging Therapeutics Market in Asia Pacific , 2022-2040 12.2.3.4. Anti-aging Therapeutics Market in Rest of the World, 2022-2040 12.2.4. Anti-aging Therapeutics: Forecast of Individual Product Sales 12.2.4.1. bioXgel (PRP) (bioXcellerator): Estimated Sales Revenues 12.2.4.2. AR-100 (Rejenevie Therapeutics): Estimated Sales Revenues 12.2.4.3. BGE-117 (BioAge Labs): Estimated Sales Revenues 12.2.4.4. Dasatinib and Quercetin (TruDiagnostic): Estimated Sales Revenues 12.2.4.5. MYMD-1 (MyMD Pharmaceuticals): Estimated Sales Revenues 12.2.4.6. TRIIM Treatment (Intervene Immune): Estimated Sales Revenues 12.2.4.7. Rapamycin (AgelessRx): Estimated Sales Revenues 12.2.4.8. Sarconeos (BIO101) (Biophytis): Estimated Sales Revenues 13. EXECUTIVE INSIGHTS 13.1. Chapter Overview 13.2. Gero.ai 13.2.1 Company Snapshot 13.2.2. Interview Transcript: Peter Fedichev (Co-founder and Chief Executive Officer) 13.3. Betterhumans 13.3.1. Company Snapshot 13.3.2. Interview Transcript: James Clement (President) 13.4. CytoMed Therapeutics 13.4.1. Company Snapshot 13.4.2. Interview Transcript: Wee Kiat Tan (Chief Operating Officer) 13.5. Cambrian Biopharma 13.5.1 Company Snapshot 13.5.2. Interview Transcript: Rosa Argyropoulos (Senior Director of Global Corporate Communications) 13.6. Landmark Medical Centre 13.6.1 Company Snapshot 13.6.2. Interview Transcript: Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist) 14. APPENDIX I: TABULATED DATA 15. APPENDIX I1: LIST OF COMAPANIES AND ORGANIZATIONS For more information about this report visit https://www.researchandmarkets.com/r/1a941t

Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:https://www.prnewswire.com/news-releases/worldwide-anti-aging-therapeutics-industry-to-2040---rising-aging-population-is-driving-growth-301569513.html

If you're starting to notice fine lines or deep wrinkles on your face or neck, dermatologists say these effective creams and serums can help smooth skin.

What would happen if Notre Dame's recruiting of the running back position could meet what it does on the offensive line?

Anyone positioning their portfolio for a recession could be making a big mistake.

“We are exiting that regime, and it’s going to be bumpy,” said the famous Fed watcher Mohamed El-Erian of the world where central banks let the money flow.

Investors might take some comfort in crystal-ball gazing by Bank of America, which uses history to plot the next bull market.

Already, very early signs of slowing demand and inflation are cropping up. If the economy averts all-out disaster, then stabilizing or declining rates would spur a market rebound.

A weekly look at the most important moves and news in crypto and what's on the horizon in digital assets.

AMD and Nvidia have been swallowed up in the bear market, with each stock declining at least 50%. Here's how to trade them now.

A decline in earnings could be the next shoe to drop for investors. But it’s all a prelude to what may be the best buying opportunity in decades.

It's no secret that Warren Buffett is one of the best investors alive, delivering investors returns of 20% compounded annually since becoming chief executive officer of Berkshire Hathaway in 1965. Numerous factors can explain Buffett's success, and an important one is his love of dividend stocks. Dividend stocks are a great source of returns in the market and, according to Fidelity, have accounted for 40% of the S&P 500's total returns since 1930.

Remember TINA? She’s the one everyone was talking about for the past few years, when it came to buying stocks. ‘There is no alternative,’ they said – pointing out that the near-zero interest rate policy has pushed bond yields down to nothing, and that the housing crisis of 2008 had left investors wary of the real estate market – and stocks were the highest returning game in town. Not anymore. The Federal Reserve has just cracked the whip on rate hikes, implementing a 0.75% increase to the benchm

(Bloomberg) -- You can look but you won’t find a stretch of futility as pervasive as the one that is landing on Wall Street.Most Read from BloombergPutin Gets Unexpected Pushback From Ally Over War in UkraineChina Says It May Have Detected Signals From Alien CivilizationsSergey Brin Seeks Divorce, Joining Gates and Bezos in SplitMusk, Tesla, SpaceX Are Sued for Alleged Dogecoin Pyramid SchemeMonkeypox Testing Shows the US Learned Little From the Covid-19 PandemicEven in the long and storied hist

Hennion & Walsh CIO Kevin Mahn and Threadneedle Ventures Founder Ann Berry join Yahoo Finance Live to talk about this week's volatile market losses, which sectors investors should look into to ford recession concerns, blockchain technology across industries, and recession risks amid rising inflation and the Fed's interest rate hikes.

Would you be interested in an asset class that produces long-term returns that are nearly as good as the stock market but is as uncorrelated with the stock market as bonds are? Residential real estate, in contrast, not only resisted stocks’ decline but actually gained in value.

Don't let its share price movement fool you. This e-commerce stock is poised to bounce back in the long run.

Retail stocks have taken a beating, but inflation, supply chain woes, and other cost concerns don't tell the full story.

(Bloomberg) -- Bitcoin fell below $20,000 for the first time since December 2020 as evidence of deepening stress within the crypto industry keeps piling up against a backdrop of monetary tightening. Most Read from BloombergPutin Gets Unexpected Pushback From Ally Over War in UkraineChina Says It May Have Detected Signals From Alien CivilizationsSergey Brin Seeks Divorce, Joining Gates and Bezos in SplitMusk, Tesla, SpaceX Are Sued for Alleged Dogecoin Pyramid SchemeMonkeypox Testing Shows the US

Credit Suisse has warned of a “new world order” in financial markets after central banks began aggressively ramping up interest rates.

The major indexes sold off on recession fears, while Bitcoin broke another key level. Tesla rival BYD is near a buy point.

These real estate investment trusts offer yields that are well over double that of the broader market, long dividend increase streaks, and favorable growth and dividend outlooks.